– IBM Watson Health unveils two new products at RNSA 2019, Clinical Review 3.0 and The Imaging AI Marketplace.
– Clinical Review 3.0, a tool recently launched in the UK that analyzes medical imaging studies and their associated reports to identify potentially missed findings, facilitating higher quality and more comprehensive care for the patient.
– The Imaging AI Marketplace is a single-source solution designed to help simplify the complex process of locating, purchasing, deploying and managing the vast array of AI imaging applications.
Today at RSNA, IBM Watson Health is announcing two new products, and showcasing a variety of partnerships and clients that are using our advanced technologies to improve the way radiologists deliver care. We are delighted to announce these collaborations at RSNA highlighting our advancements in medical imaging globally,” said Anne Le Grand, General Manager, Imaging, Life Sciences, and Oncology, IBM Watson Health. “From helping clinicians to identify potential missed findings to seeing a summary view of patient records quickly, our innovative technologies are at the forefront of Watson Health’s mission to help enable clinicians to more effectively respond to the world’s most pressing health challenges.”
2 New Imaging Solutions
Clinical Review 3.0, a tool recently launched in the UK that analyzes medical imaging studies and their associated reports to identify potentially missed findings, facilitating higher quality and more comprehensive care for the patient. IBM Watson Health Imaging has recently engaged with Fortrus Ltd, to grow upon the reseller’s strong relationship with the UK public sector, which includes a single supplier outcome-based Managed Services framework.
The Imaging AI Marketplace is a single-source solution designed to help simplify the complex process of locating, purchasing, deploying and managing the vast array of AI imaging applications. The Imaging AI Marketplace is carefully curated and contains only FDA-cleared solutions alongside Watson Health developed AI solutions. The four vendor partners for the Imaging AI Marketplace are:
– Circle Cardiovascular Imaging
– DiA Imaging Analysis Ltd.
– MaxQ AI
– Quantib BV
– VIDA LungPrint
Guerbet Signs Exclusive Development Agreement for AI in Prostate Cancer
Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional imaging, also recently signed an exclusive joint development agreement to develop an artificial intelligence software solution to support prostate cancer diagnostics and monitoring, utilizing MR imaging. This deal extends their earlier collaboration regarding liver cancer signed in January 2018.
4ways Healthcare Limited Adopts IBM Watson Health Imaging Merge PACS
In addition, 4ways, a fast-growing private teleradiology network in the UK that enables UK-based radiologists to work remotely over a leading technology platform, has committed to underpin its ambitious growth strategy with IBM Watson Health’s Merge PACS 8.0 platform, upgrading its current platform to support their business growth. Merge PACS™ is a workflow platform that is designed to help simplify physicians’ reading activities and can empower IT leaders with advanced control of the flow of studies throughout the enterprise.
“We’re committed to constantly investing in and upgrading our IT provision to be able to offer our clients and partners the very best service. That means working with the best tech providers in our space. We’ve used Merge solutions successfully for many years so continuing with IBM Watson Health imaging solutions was a natural next step. Merge PACS is designed to handle high-enterprise imaging volumes, perform in diverse reading environments, and helps us to scale our delivery of care,” said Ajay Chadha, CEO, 4ways.
